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Abstract
Background: Nutrition and lifestyle have been long established as risk factors for colorectal cancer (CRC).
Modifiable lifestyle behaviours bear potential to minimize long-term CRC risk; however, translation of lifestyle
information into individualized CRC risk assessment has not been implemented. Lifestyle-based risk models may aid
the identification of high-risk individuals, guide referral to screening and motivate behaviour change. We therefore
developed and validated a lifestyle-based CRC risk prediction algorithm in an asymptomatic European population.
Methods: The model was based on data from 255,482 participants in the European Prospective Investigation into
Cancer and Nutrition (EPIC) study aged 19 to 70 years who were free of cancer at study baseline (1992–2000) and
were followed up to 31 September 2010. The model was validated in a sample comprising 74,403 participants
selected among five EPIC centres. Over a median follow-up time of 15 years, there were 3645 and 981 colorectal
cancer cases in the derivation and validation samples, respectively. Variable selection algorithms in Cox proportional
hazard regression and random survival forest (RSF) were used to identify the best predictors among plausible
predictor variables. Measures of discrimination and calibration were calculated in derivation and validation samples.
To facilitate model communication, a nomogram and a web-based application were developed.
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Results: The final selection model included age, waist circumference, height, smoking, alcohol consumption,
physical activity, vegetables, dairy products, processed meat, and sugar and confectionary. The risk score
demonstrated good discrimination overall and in sex-specific models. Harrell’s C-index was 0.710 in the derivation
cohort and 0.714 in the validation cohort. The model was well calibrated and showed strong agreement between
predicted and observed risk. Random survival forest analysis suggested high model robustness. Beyond age, lifestyle
data led to improved model performance overall (continuous net reclassification improvement = 0.307 (95% CI
0.264–0.352)), and especially for young individuals below 45 years (continuous net reclassification improvement =
0.364 (95% CI 0.084–0.575)).
Conclusions: LiFeCRC score based on age and lifestyle data accurately identifies individuals at risk for incident
colorectal cancer in European populations and could contribute to improved prevention through motivating
lifestyle change at an individual level.
Keywords: Colorectal cancer, Risk prediction, Lifestyle behaviour, Risk screening, Cancer prevention
Background
Colorectal cancer accounted for over 1.8 million new
cases or 10% of all new cases of cancer worldwide in
2018 [1]. Worryingly, the global burden of colorectal
cancer is expected to rise by 60% reaching 2.2 million
new cases and 1.1 million deaths in 2030, with European
countries ranking highest in the global statistics of colo-
rectal cancer incidence and mortality [2]. The projected
increase in colorectal cancer burden necessitates im-
proved assessment of primary prevention strategies [2,
3]. Targeted prevention in an asymptomatic population
that addresses potentially modifiable factors has poten-
tial for reducing lifestyle-associated long-term risk of
colorectal cancer and represents a cost-effective ap-
proach to reduce the cancer burden [4, 5].
Lifestyle behaviours such as smoking, alcohol consump-
tion, and poor diet have long been recognized to be asso-
ciated with a higher risk of colorectal cancer [6–15].
Updated evidence on nutrition and cancer risk further
highlighted the importance of risk factors such as body
fatness (i.e. abdominal adiposity), adult-attained height,
physical activity, high intake of red and processed meat
and low intakes of whole grains, dairy products and fish
[15, 16]. Despite accumulation of evidence, translation of
lifestyle information into individualized colorectal cancer
risk assessment strategies has not been implemented so
far. Risk stratification may aid the identification of high-
risk individuals, guide referral to screening and motivate
lifestyle modification [17]. Individualized risk estimates in
primary care may essentially aid behaviour change and
complement preventive approaches to shifting population
distributions of risk factors [17].
A number of colorectal cancer risk prediction models
have been published over the last decade [18–21]. Most
published models have been predominantly developed
using data from American and Asian populations [18,
19]. We have previously validated several models in
European populations based on data from UK Biobank
and the European Prospective Investigation into Cancer
and Nutrition (EPIC) cohort studies [20]; however, sev-
eral gaps remain to be addressed. First, only a few previ-
ous models have been developed based on prospective
cohort data with long enough follow-up time to account
for the potentially long latency period of colorectal can-
cer development [18]. Second, important emerging pre-
dictors related to nutrition and lifestyle such as
abdominal fatness have not been considered [22]. Third,
most models focused only on model development and
did not address the full continuum of model develop-
ment, validation and communication recommended in
recent methodological guidelines for research on risk
prediction (i.e. TRIPOD, Transparent Reporting of a
multivariable Prediction model for Individual Prognosis
or Diagnosis) [19, 23]. Fourth, previous models were
mostly developed using logistic regression and did not
account for time-to-event. New approaches such as pe-
nalized regression methods (i.e. elastic net regression)
and machine learning algorithms (i.e. random survival
forest) might offer additional means for model improve-
ment [24, 25]. Finally, model communication to the
wider public was generally not addressed by previous
studies and was restricted to providing a formula to cal-
culate individual absolute risk of colorectal cancer [18].
Graphical nomograms and web-based applications could
further aid in facilitating model communication [26].
In this context, we aimed to develop and validate a
lifestyle-based risk prediction model for the prevention of
colorectal cancer in a population-based European cohort.
We further aimed to construct a simple and widely applic-
able user-friendly risk calculator offering an estimate of
colorectal cancer risk based on individual’s personal data.
Methods
Study design and data source
The lifestyle-based prediction model for colorectal can-
cer risk (LiFeCRC score) was developed using data
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collected within EPIC, a multicentre prospective cohort
study comprising 521,324 participants aged 17 to 98
years at study baseline (predominantly 35 to 70 years) re-
cruited between 1992 and 2000 across 23 centres in 10
European countries [27]. Participants included blood do-
nors, screening participants, health-conscious individuals
and the general population. Written informed consent
was obtained from all participants before joining the
EPIC study. Approval for the EPIC study was obtained
from the ethical review boards of the International
Agency for Research on Cancer and from all local insti-
tutions through which subjects were recruited for the
EPIC study, as previously reported [28].
Case ascertainment
The primary outcome was incident colorectal cancer.
Cancer cases were identified through population cancer
registries in Denmark, Italy, the Netherlands, Spain,
Sweden and the UK. In France, Germany and Greece, a
combination of methods was used including health in-
surance records, cancer pathology registries and active
follow-up of study participants. Follow-up began at the
date of enrolment and ended at the date of diagnosis of
colorectal cancer, death or last complete follow-up. The
last update of endpoint information was done up to 31
September 2010. Colon and rectal cancers were defined
according to the 10th Revision of the International Statis-
tical Classification of Diseases, Injuries and Causes of
Death (ICD-10), proximal colon tumours include tumours
in the cecum, cecal appendix, ascending colon, hepatic
flexure, transverse colon and splenic flexure (ICD-10
codes C18.0–18.5); distal colon tumours include those in
the descending colon (ICD-10 code C18.6) and sigmoid
colon (ICD-10 code C18.7); and rectal tumours are those
occurring at the rectosigmoid junction (ICD-10 code C19)
or in the rectum (ICD-10 code C20). Only the first pri-
mary neoplasm was included in the analysis; non-
melanoma skin cancer was excluded.
Study population
Figure 1 presents a flowchart of study population selec-
tion for deriving the LiFeCRC score in the EPIC cohort.
EPIC study (recruited 1992 to 2000)
521,324 participants
Colon cancer:  4,044 cases
Rectal cancer: 2,180 cases
329,885 participants
Colon cancer:  2,847 cases
Rectal cancer: 1,560 cases
Excluded participants:
Prevalent diseases
Other cancers 27,787   (5.3 %)
Diabetes 13,049   (2.5 %)
Myocardial infarction 5,660   (1.1 %)
Stroke 3,078   (0.6 %)
Undefined follow-up status 1,493   (0.3 %)
Incorrect follow-up dates 359   (0.1 %)
Age ≥70 years 10,418   (2.0 %)
Underweight 5,989   (1.1 %)
(BMI <18 kg/m²)
Extreme energy intake 6,308   (1.2 %)
(<500 kcal or >5,000 kcal)
Missing data on main factors
Waist circumference 107,959 (20.7 %)
Physical activity 6,416   (1.2 %)
Smoking status 2,923   (0.6 %)
Derivation cohort
255,482 participants
Colon cancer:  2,287 cases
Rectal cancer: 1,199 cases
Validation cohort
74,403 participants
Colon cancer:  560 cases




Colon cancer:  975 cases




Colon cancer: 1,312 cases




Colon cancer:  255 cases




Colon cancer:  305 cases









Italy (Florence, Ragusa, Turin, Naples)
Spain (Granada, Murcia, Navarra, San Sebastian)






Fig. 1 Flowchart of study population selection
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Participants with prevalent cancer, diabetes, myocardial
infarction or stroke at recruitment and participants with-
out follow-up were excluded. Missing information on
main risk factors (sex, anthropometric measurements,
lifestyle and dietary data) was present in 22.5% of the
data, and therefore, entries with missing data were ex-
cluded for complete case analysis. Based on this, partici-
pants from EPIC-Umeå and EPIC-Norway were
excluded from the current analyses due to lack of data
on waist circumference measurements. The resulting
study sample comprised 329,885 participants among
which 4626 incident colorectal cancer cases (2847 colon
cancer/1560 rectal cancer) were diagnosed during study
follow-up. This sample was split into a derivation cohort
(N = 255,482) and a validation cohort (N = 74,403) on a
non-random principle following the TRIPOD recom-
mendations [23]. The derivation sample included par-
ticipants from 21 EPIC centres in France, Italy, Spain,
UK, the Netherlands, Greece, Germany, Sweden and
Denmark. The validation sample included participants
representing Southern and Northern European popu-
lations from 5 EPIC centres in Italy, Spain, the
Netherlands, Germany and Denmark (Fig. 1).
Baseline data collection
At baseline, participants completed extensive medical,
dietary and lifestyle questionnaires, including questions
on alcohol use, smoking status, physical activity, educa-
tion and previous illnesses. Body weight, height and
waist circumference were measured in all centres except
for EPIC-Oxford (health-conscious population) and
EPIC-France where anthropometric measurements were
self-reported [27]. Usual food intakes were measured by
using country-specific validated dietary questionnaires
[29]. All dietary variables used in the present study were
calibrated by using an additive calibration method as
previously described [30]. Non-steroidal anti-inflammatory
drug (NSAID) use was only assessed in the Cambridge
study center, and family history of colorectal cancer was
assessed only in study centres in France, Spain and the UK.
Baseline characteristics of participants with available
information on NSAID use and family history of colo-
rectal cancer are presented in Supplementary Table 1,
Additional File 1.
Model development
The model development and model validation were per-
formed and reported following the TRIPOD guidelines
[23, 31] (Supplementary Table 2, Additional File 1). The
general workflow of model derivation, performance
evaluation, validation and model communication are
presented in Supplementary Fig. 1, Additional File 2.
Overall, the LiFeCRC score was derived based on beta
coefficients for colorectal cancer risk estimated in Cox
proportional hazard models within the derivation data-
set. Time -to - event was defined as time from baseline
assessment to first cancer event. Supplementary Table 3,
Additional File 1 presents the variable names and meas-
urement scales of a predefined set of 16 predictors se-
lected based on published literature reflecting latest
evidence from systematic reviews (i.e. World Cancer
Research Fund/American Institute for Cancer Research
reports) and based on availability of data in the EPIC co-
hort. Analyses based on Schoenfeld residuals and stratified
Kaplan-Meier curves revealed no violation of the propor-
tional hazard assumption of the Cox model. To test
whether the predictive performance of each variable is the
same, regardless of the values of other predictors, statis-
tical interactions between different combinations of pre-
dictor variables on the multiplicative scale were tested
using the likelihood ratio test. Since model discrimination
was not improved by including significant interaction
terms, the inclusion of interaction terms in the final Cox
models was disregarded to avoid overfitting.
Elastic net selection
Predictor variable selection was performed using boot-
strapped elastic net regularization [32]. Elastic net
regularization is a penalized regression method, combining
least absolute shrinkage and selection operator (LASSO)
and ridge regression. A penalty parameter λ is used to
shrink predictor regression coefficients, eventually remov-
ing predictor variables from the model by setting their re-
spective regression coefficient to zero. A mixing parameter
α is used to fix the proportion for combining LASSO and
ridge regression. Optimal values for both parameters λ and
α were determined based on minimal mean error of 10-fold
cross-validation using 100 possible λ values for α values be-
tween 0.5 and 1 (0.5, 0.6, 0.7, 0.8, 0.9, 1). The selected pa-
rameters were then used to bootstrap the elastic net
regularization of each predictor’s Cox regression coefficient
with 1000 replications. Based on all bootstrap replications,
mean coefficient values and 95% confidence intervals were
calculated for each predictor coefficient. Predictors with
confidence intervals including zero were removed. All
remaining predictors were then used to generate reduced
elastic net penalized Cox regression models. The model se-
lection was conducted for colorectal cancer as a single end-
point (LiFeCRC score) and according to sex and cancer
subsite (colon/rectum). Variable selection and Cox regres-
sion modeling were performed using R 3.6.1 (R Core Team)
[33], and the glmnet (version 2.0-18) [34] and survival (ver-
sion 2.44-1.1) [35] packages.
Absolute risk assessment
The individual 10-year absolute risk P (10y) for colorec-
tal cancer was calculated using the following formula:
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Pð10yÞ ¼ 1 − Smð10yÞexpðRisk Scorei − Risk ScoremÞ
The 10-year survival function estimate Sm (10y) was
calculated for average predictor variable values. The
average Risk Scorem and the individual Risk Scorei were








β j  predictor valueij
The j index stands for a predictor variable of a Cox re-
gression model and βj is the beta estimate.
In additional analyses, the study population was strati-
fied according to predefined risk categories of low, inter-
mediate and high risk, based the 50th and 90th percentile
of predicted risk in the derivation cohort. Incidence rates
and model selection characteristics across the so defined
risk categories in both the derivation and validation sam-
ples have been assessed.
Model performance: discrimination and calibration
Model discrimination
Model discrimination was assessed based on Harrell’s C-
index as a measure similar to the receiver operating
characteristic statistic that takes the censored nature of
data into account. This value represents the odds of the
predicted probability of developing colorectal cancer be-
ing higher for those who actually develop colorectal can-
cer compared to those who do not develop the disease.
To account for model optimism in terms of overfitting,
bootstrapping with 1000 replications was performed. In
bootstrapping, entries are randomly drawn with replace-
ment from a data set until the bootstrap sample has the
size as the original dataset. For each bootstrap sample,
an elastic net penalized Cox regression model was fitted.
Harrell’s C-index of each bootstrap model was then cal-
culated for the bootstrap sample and the original data in
each bootstrap replication. The difference of these values
was averaged over all 1000 bootstrap replications to cal-
culate the amount of optimism for the C-index of the
original model, which was used to calculate an
optimism-corrected C-index. This analysis was per-
formed in R [33] with the package rms (version 5.1-3.1)
[36].
Model calibration
Calibration plots of estimated individual predicted risks
of developing colorectal cancer in the next 10 years were
derived from the penalized Cox regression model. These
values were divided into deciles, and each decile’s mean
value was computed. The Kaplan-Meier survival func-
tion at 10 years with 95% confidence interval was calcu-
lated for each decile group. Subsequently, the trend of
the mean predicted risks and the observed complement
of the Kaplan-Meier survival of each decile was visually
compared as a measure of calibration. Model perform-
ance, including Harrell’s C-index and calibration plots,
was also evaluated in the validation cohort.
Model communication
In order to assist the translation of the generated statis-
tical model into an individual risk prediction equation,
we created a 10-year risk assessment nomogram as a
graphical model representation that allows risk estima-
tion. For this purpose, we used the R [33] package rms
(version 5.1-3.1) [36]. In addition, we developed a user-
friendly risk calculator application using the R [33] pack-
ages shiny (version 1.2.0) [37] and shinydashboard (ver-
sion 0.7.1) [38] that can be adapted for a web-based use.
This application allows the prediction of individual colo-
rectal cancer risk by including characteristics into input
fields. The input values are then evaluated using the vali-
dated colorectal cancer risk prediction model.
Random survival forest
Random survival forest was used as an alternative ma-
chine learning method in order to prove model robust-
ness, i.e. assess whether the same set of predictors will
be selected. Each random survival forest was generated
with a total number of 500 decision trees with 100
unique data points on average in each terminal node
and a maximum of 10 possible random split points to
consider at each branch of a decision tree. A variable
importance measure for each predictor variable, describ-
ing the impact of using randomly permuted values of
this variable instead of observed values for the prediction
of known entries, was then extracted from the random
survival forest. For the computation of random survival
forests, the package “randomForestSRC” (version 2.6.1)
was used. Model performance was evaluated in the der-
ivation and validation cohort using Harrell’s C-index
and calibration plots.
Sensitivity analyses
In sensitivity analyses, we evaluated the added predictive
value of lifestyle data beyond age, using the following
statistics: (1) improvement in model discrimination—
based on goodness of fit (likelihood ratio test), estimated
net change in Harrell’s C-index and continuous net re-
classification improvement (NRI> 0); (2) improvement in
model calibration based on comparison of calibration
plots and (3) net benefit of the model based on decision
curve analysis. We also stratified the study population in
the derivation and validation sample according to age
groups: < 45 years; 45–65 years; > 65 years and calculated
model performance characteristics (Harrell’s C-index
and NRI> 0) for the lifestyle-based model across these
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categories. In addition, we also calculated the predicted
10-year absolute risk of colorectal cancer for a prede-
fined “healthy” and “unhealthy” lifestyle pattern across
different age groups and a constant body height. In
subsample of the derivation cohort with available infor-
mation, Harrell’s C-index was compared between models
with and without inclusion of NSAID use or family
history. To address model generalizability, we further
evaluated model performance across subgroups by
selected variables, i.e. waist circumference, education,
smoking status (including level of smoking intensity)
and level of alcohol consumption. Finally, to account
for the potential influence of competing risk of death
(N = 23,774), we calculated the cumulative incidence
adjusted for mortality and evaluated the discrimin-
ation of the reduced model based on Fine-Gray sub-
distribution hazard regression [39] in both the
derivation and validation samples.
Results
Baseline characteristics
Table 1 shows the baseline characteristics of men and
women in the derivation and validation cohorts.
Overall, the distribution of risk factors was similar
across both cohorts. In the derivation cohort, the
mean age at study baseline was 51.4 years, 67.5% of
the participants were women, and mean age at colo-
rectal cancer diagnosis was 66.0 years in women and
66.4 years in men. Never-smokers, physically active
and highly educated people comprised 49.1%, 10.3%
and 24.6% of the derivation cohort, respectively. The
median follow-up time was 15.4 (interquartile range
13.2 to 16.9) years in the derivation cohort and 14.1
(interquartile range 10.5 to 16.0) years in the valid-
ation cohort.
Model development
Figure 2 illustrates the distribution of Cox regression co-
efficients of all predictor variables based on the boot-
strapped elastic net regularization. Selected variables in
the reduced model are highlighted based on the selec-
tion criterion of having a coefficient value of 0 not in-
cluded in the 95% confidence interval. Table 2 shows
derived colorectal cancer hazard ratios for all risk factors
(full model) and risk factors that remained after elastic
net selection (reduced model). The selected predictors of
the overall colorectal cancer risk in men and women
included age, waist circumference, height, daily alcohol
consumption, smoking, physical activity, vegetables,
dairy products, processed meat, and sugar and confec-
tionary (Table 2). The models derived separately for
men and women confirmed age, waist circumference,
smoking and vegetable intake as consistent predictors
across both genders. Additional predictors retained in
the reduced model in men were daily alcohol consump-
tion, dairy intake, dark bread and red meat, and in
women, height and processed meat. The estimated 10-
year mean absolute risk for colorectal cancer of the der-
ivation cohort was 0.78% in both sexes, 1.07% in men
and 0.64% in women (Table 2). Table 3 provides an
overview of selected variables by anatomical subsite,
colon and rectal cancer, overall and separately in men
and women. An additional predictor that was retained in
the model for rectal cancer was the intake of soft drinks.
Notably, selected predictors in women were somewhat
different for colon and rectal cancer. For colon cancer,
the model included age, waist circumference, height,
smoking and vegetable intake, whereas for rectal cancer
it included age, processed meat and soft drinks
(Table 3).
Model performance: discrimination and calibration
Overall model discrimination was good with Harrell’s
C-index of 0.709 for the derived colorectal cancer risk
model. Optimism-adjusted Harrell's C index ranged
from 0.667 for the model for rectal cancer in women
to 0.716 for the model for colon cancer in both sexes
(Table 4). Reduced models showed similar predictive
performance as the “full models” suggesting that
obtaining data on selected predictors would yield suf-
ficient information and additional factors are not add-
ing predictive value to the model. The performance
in the validation cohort was similar for all models,
suggesting a high level of stability and a lack of over-
fitting. Calibration plots of derived colorectal cancer
risk models in the derivation and validation sample
overall and by sex are presented in Fig. 3. An overall
good calibration was observed based on the compar-




To provide assessment of the absolute 10-year risk of
colorectal cancer for individuals with various combina-






¼ 1 − Smð10 yearsÞexpðRisk Scorei − Risk ScoremÞ
¼ 1 − 0:9943expðRisk Scorei − 6:8089Þ
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Risk Scorei ¼ 0:0781 Agei ðyearsÞ
þ0:0117Waist circumferencei ðcmÞ
þ0:0115 Body heighti ðcmÞ
þ0:1292 Daily alcoholi ðyes ¼ 1;no ¼ 0Þ
þ0:2125 Smokingi ðyes ¼ 1;no ¼ 0Þ
− 0:0964 Physically activei ðyes ¼ 1; no ¼ 0Þ
− 0:0773 Vegetable intakei ðper 100g=dayÞ
− 0:0166 Dairy products intakei ðper 100g=dayÞ
þ0:0808 Processed meat intakei ðper 50g=dayÞ
þ0:0268 Sugar and confectionaryi ðper 50g=dayÞ
Values for Sm (10 years) and Risk Scorem are given in
Table 2. Absolute risk for different timespans can be calcu-
lated by replacing Sm in the formula accordingly. The sur-
vival function estimates for timespans between 0 and 20
years are shown in Supplementary Fig. 2, Additional File 2.
Incidence rates and model selection characteristics across
predefined risk categories (low, intermediate and high risk)
with cut points at 0.62% and 1.60% 10-year absolute risk
are presented in Supplementary Table 4, Additional File 1,
for both the derivation and validation sample.
Nomogram
Figure 4 shows a nomogram of the weights and points
of the colorectal cancer risk prediction score allowing
estimation of an individual’s probability to develop colo-
rectal cancer over a 10-year period. The nomogram is
characterized by a scale corresponding to each variable,
a point scale, a total point scale and a probability scale.
The use of the nomogram is simple and involves 3 steps.
First, on the scale for each variable, the value corre-
sponding to a specific individual is read and the point
scale is used to calculate the points for all variable
values. Second, the total number of points is calculated
by adding up all the points obtained in the previous step,
and its value is identified on the total point scale. Finally,
the probability of an event corresponding to the total
points of the individual is represented on the risk scale.
As a practical example, we estimated the 10-year risk of
colorectal cancer, for individuals with two different com-
binations of ages and lifestyle factors, representing low-
risk and high-risk extremes: individual 1 was 45 years
old (50 points) with a body height of 166 cm (7.5 points),
a waist circumference of 70 cm (3 points) and healthy
lifestyle behaviour (low daily alcohol consumption (0
points), non-smoker (0 points), physically active (0
points), 430 g daily vegetable intake (7 points), 630 g
daily dairy products intake (2.5 points), 0 g daily proc-
essed meat intake (0 points), and 5 g daily sugar and
confectionary intake (0 points)), and individual 2 was 65
years old (90 points) with a body height of 166 cm (7.5
points), a waist circumference of 100 cm (12 points) and
rather unhealthy lifestyle behaviour (high daily alcohol
consumption (3 points), smoker (5 points), physically in-
active (2.5 points), 80 g daily vegetable intake (14.5
points), 70 g daily dairy products intake (5 points), 60 g
daily processed meat intake (2.5 points), and 90 g daily
sugar and confectionary intake (1.5 points)). The total
number of points of the various prediction indicators
was ~ 70 and ~ 143.5 and the corresponding absolute
predicted 10-year risk of colorectal cancer was ~ 0.2%
(risk score of ~ 5.7) and ~ 3–3.5% (risk score of ~ 8.6)
for individual 1 and individual 2, respectively.
Web-based calculator
As an alternative approach to model communication, we
developed a web-based calculator for the estimation of a
Fig. 2 Average Cox regression coefficients with 95% confidence intervals after bootstrapped elastic net regularization. Bootstrapping was
performed over 1000 repetitions. Selected variables with a confidence interval not including 0 are highlighted in red
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personalized colorectal cancer risk based on the vali-
dated LiFeCRC score. A graphical illustration of the ap-
plication layout with predicted and absolute risk values
for a modifiable time span is presented in Fig. 5. Of note,
the results produced by the web-based calculator should
be interpreted considering that competing risk of mor-
tality was not included in the absolute risk calculation.
Random survival forest
Results of random survival forest-based relative variable
importance for colorectal cancer risk prediction are pre-
sented in Supplementary Fig. 3, Additional File 2. The
main selected predictors remained similar as in the Cox
regression model, confirming model robustness. The
highest relative importance was observed for age,
followed by waist circumference, red and processed meat
intake, height and vegetable consumption. The model
for women showed, in addition, height, dark bread and
dairy products intake as additional important predictors,
whereas the model for men showed smoking and sweets
and confectionary consumption as additional important
predictors. Overall, the discrimination (Supplementary
Fig. 3, Additional File 2) and calibration (Supplementary
Fig. 4, Additional File 2) of the random survival forest
based colorectal cancer risk prediction model was com-
parable to the Cox regression model.
Sensitivity analysis
In a sensitivity analysis, we evaluated to what extent life-
style data added predictive value to the colorectal cancer
risk model based on age only. The addition of the life-
style variables resulted in a statistically significantly in-
creased goodness of fit (likelihood ratio test p < 0.001).
The estimated NRI> 0 was 0.307 (95% confidence interval
0.264 to 0.352) indicating an improvement in model per-
formance. Supplementary Fig. 5, Additional File 2
Table 4 Model selection and discrimination in the derivation and validation cohorts
Colorectal cancer Colon cancer Rectal cancer
Selected predictors Both sexes Men Women Both sexes Men Women Both sexes Men Women
Age at recruitment, per 10 years ● ● ● ● ● ● ● ● ●
Waist circumference, per 10 cm ● ● ● ● ● ● ●
Height, per 10 cm ● ● ● ● ●
Daily alcohol consumption, high ● ● ● ● ●
Ever smoker, yes ● ● ● ● ● ● ● ●
Physically active, yes ● ● ●
Vegetables, per 100 g/day ● ● ● ● ● ● ● ●
Fruits, per 100 g/day
Dark bread, per 50 g/day ● ● ●
Dairy products, per 100 g/day ● ● ● ●
Red meat, per 50 g/day ●
Poultry, per 50 g/day
Processed meat, per 50 g/day ● ● ● ●
Fish, per 50 g/day
Sugar and confectionary, per 50 g/day ●
Soft drinks, per 100 g/day ● ●
Harrell’s C-index
Full model
Derivation cohort 0.710 0.700 0.702 0.718 0.708 0.718 0.705 0.705 0.677
Optimism corrected * 0.708 0.697 0.700 0.716 0.707 0.715 0.704 0.703 0.668
Validation cohort 0.715 0.707 0.700 0.708 0.727 0.700 0.730 0.689 0.693
Reduced model
Derivation cohort 0.710 0.699 0.700 0.717 0.705 0.717 0.703 0.700 0.668
Optimism corrected* 0.709 0.698 0.699 0.716 0.704 0.715 0.701 0.698 0.667
Validation cohort 0.714 0.708 0.699 0.708 0.727 0.698 0.728 0.687 0.696
*Harrell's C-index for the derivation cohort corrected for optimism by bootstrapping with 1000 replications. For each bootstrap sample a new model is fitted and
the C-index calculated for the bootstrap sample and the original derivation cohort. The difference between these two C-indices is then averaged over all
bootstrap replications and then subtracted from the original C-index
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displays the model calibration and net benefit curves for
an aged-based model and the LiFeCRC model that add-
itionally included lifestyle factors for overall colorectal
cancer. An improved calibration and higher net benefit
were observed for colorectal cancer risk thresholds be-
tween 0.7 and 2.5% for the LiFeCRC model compared to
the age-based model. In analyses stratified according to
age groups, model performance was higher in individuals
< 45 years and adding lifestyle data contributed to im-
proved reclassification statistics, i.e. higher NRI> 0, sug-
gesting relative importance of lifestyle data assessment
for risk prediction at younger ages (< 45 years), i.e.
NRI> 0 = 0.364 (95% confidence interval 0.084 to 0.575)
(Supplementary Table 5, Additional File 1). We further
estimated the predicted 10-year absolute risk of colorec-
tal cancer for an arbitrary predefined “healthy” and “un-
healthy” lifestyle, across different age groups and a
constant body height (Supplementary Fig. 6, Additional
File 2). For example, an individual aged 45 years with a
body height of 166 cm adopting a predefined “unhealthy
lifestyle” (waist circumference of 100 cm, high daily alco-
hol consumption, smoker, physically inactive, 80 g daily
vegetable intake, 70 g daily dairy products intake, 60 g
daily processed meat intake and 90 g daily sugar and
confectionary intake) has a 3.6 times higher absolute risk
of colorectal cancer within the next 10 years compared
Fig. 3 Calibration plots of 10-year colorectal cancer risk. Predicted risk is compared against observed risk in the derivation and validation cohorts,
overall and by sex. Observed risk is based on the complement of the Kaplan-Meier survival curve
Fig. 4 Nomogram of colorectal cancer absolute risk prediction over 10 years
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to a person of the same age and body height, adopting a
predefined “healthy lifestyle” (waist circumference of 70
cm, low daily alcohol consumption, non-smoker, physic-
ally active, 430 g daily vegetable intake, 630 g daily dairy
products intake, 0 g daily processed meat intake and 5 g
daily sugar and confectionary intake). In a subsample
with available information, addition of information on
NSAID use or family history of colorectal cancer to the
list of predictors did not further improve model per-
formance beyond main lifestyle variables (Supplementary
Fig. 7, Additional File 2). The results did not reveal
marked differences in model discrimination among sub-
groups by waist circumference, education, smoking sta-
tus and levels of alcohol consumption (Supplementary
Table 6, Additional File 1). Furthermore, no substantial
differences could be seen between the Kaplan-Meier sur-
vival function and the cumulative incidence function
taking competing risk into account (data not shown).
Also, no differences in the discrimination ability of the
Fine-Gray model taking competing risk of death into ac-
count could be observed (C-index = 0.710).
Discussion
In this large European prospective cohort study, we de-
veloped and validated the LiFeCRC score, as a lifestyle-
based prediction model for the prevention of colorectal
cancer in asymptomatic populations across Europe. Be-
yond age, the variables retained in the model were waist
circumference, height, daily alcohol consumption, smok-
ing status, physical activity and dietary intakes of vegeta-
bles, dairy products, processed meat and sugar and
confectionary. Separate models were also developed for
men and women and for colon and rectal cancer sub-
types. The model showed good calibration and discrim-
ination properties to identify individuals at all levels of
colorectal cancer risk. Modifiable lifestyle factors con-
tributed to model performance and accuracy beyond age
alone and could improve reclassification statistics
Fig. 5 Application for the colorectal cancer risk model. Example for a hypothetical individual data entry and risk calculation
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especially in younger age groups (< 45 years). A user-
friendly colorectal cancer risk nomogram and a web cal-
culator were developed to facilitate model
communication.
Currently, the target population for colorectal cancer
screening is mainly selected based on age alone (i.e. 50 years
or above). Although age is undoubtedly an important pre-
dictor of colorectal cancer as shown in our data, informa-
tion on modifiable lifestyle factors allows provision of
preventive health recommendations for individuals at risk
[40]. Lifestyle-based models have been suggested in medical
practice as important tools that could be used to identify
those most likely to benefit from lifestyle interventions and
to contribute to behaviour change interventions [41]. A
number of intervention studies focusing on changing life-
style for colorectal cancer prevention reported significant
effects on the target behaviours [42–46]. In those studies,
tailored approaches that enable personalized feedback re-
garding individual lifestyle patterns were suggested as more
successful compared to generic approaches [42–47]. Des-
pite lifestyle interventions representing a powerful cost-
effective strategy for colorectal cancer prevention, there has
been little incentive on the side of health professionals to
advocate lifestyle-based recommendations [48]. Risk assess-
ment tools such as the LifeCRC score could facilitate im-
proved advocacy on the side of health professionals and
motivate or empower individuals to implement behaviour
changes [47, 49]. Targeting lifestyle factors in those at high-
est risk may be particularly relevant for younger age groups
that may profit most from early preventive interventions
aimed at encouraging behavioural changes [47].
A number of previous models incorporated lifestyle
data with common covariates including self-reported
BMI (body mass index), alcohol consumption and smok-
ing [18–21]. Recently, a model based on BMI, smoking,
alcohol, red and processed meat, fruits, vegetables and
physical activity demonstrated C-statistics of 0.66 and
0.68 in men and women, respectively [41]. Compared
with this and other published models that also include
family history and more complex variables [18, 19, 50,
51], the EPIC lifestyle-based model showed a compar-
able and even improved performance based on Harrell’s
C-index of 0.710 in both derivation and validation cohort.
As previously reported, the highest C-statistic for colorectal
cancer risk prediction model ranged from 0.67 in UK Bio-
bank to 0.69 EPIC validation samples [20]. Compared to
our model, that model included 13 variables: age, ethnicity,
education, BMI, family history, diabetes, oestrogen expos-
ure, non-steroidal anti-inflammatory use, physical activity,
smoking, alcohol, red meat intake and multivitamin use.
Having the strong discrimination statistics for models based
on age alone, additional predictors were shown to add little
improvement to model C-statistics in previous studies as
well as in our data [18, 20, 51]. To address the question
whether lifestyle information is important for absolute risk
assessment beyond age, we evaluated the model perform-
ance across different age groups. These results showed that
the model performance was highest in the group of partici-
pants < 45 years old and suggested this age period as a rele-
vant time window for early cancer prevention. We further
calculated the 10-year absolute risk of colorectal cancer
across different ages comparing predefined “healthy” versus
“unhealthy” lifestyle pattern based on selected model pre-
dictors. These analyses suggested that at a given age and
height, i.e. for an individual aged 45 years with a body
height of 166 cm, following the unhealthy lifestyle pattern
would lead to 3.6 times higher absolute risk of colorectal
cancer within the next 10 years compared to a person of
the same age and body height, adopting a healthy lifestyle.
These results highlight the importance of adherence to
healthy lifestyle for the long-term reduction of colorectal
cancer risk. In support of these data, recent analysis based
on a large German population sample showed that healthy
lifestyle could improve prospects for avoiding colorectal
cancer in the long term even beyond individual genetic risk
[52].
The elaborated phenotyping and detailed assessment of
nutritional data in the EPIC cohort allowed selection of
several factors not commonly depicted in previous colo-
rectal cancer risk prediction models. Compared to previ-
ous models that used data on self-reported BMI, in the
EPIC cohort data was available on waist circumference
measurements and these were among the main predictors
[53, 54]. Unlike BMI which does not take body fat distri-
bution into account, waist circumference provides a proxy
for the centrally located visceral fat shown especially rele-
vant for colorectal cancer development [53, 55]. Only a
few previous models included data on height which was
selected as another important predictor by our model [56,
57]. Greater height could provide reflection of an in-
creased standard of living characterized by greater avail-
ability of energy and protein-rich foods, lower physical
activity and a reduced incidence of childhood infections
that follow different patterns across Europe [58]. Physical
activity was also selected as a predictor of colorectal can-
cer risk, particularly in the model for women. These data
support recent findings from the Women’s Health Initia-
tive [59] and the overall notion of the importance of phys-
ical activity for the prevention of colorectal cancer [60].
Beyond red meat [56, 57, 61] and vegetable intake [56,
62–64], additional dietary predictors selected by our
model included low dairy intake and high intakes of sug-
ary products, including soft drinks. Guiding individuals to-
wards healthy dietary and lifestyle choices
could complement colorectal cancer screening as means
for colorectal cancer prevention.
The selected model performed similarly well as the model
with the full list of predictors, suggesting that it can be used
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as a simpler approach for determining high-risk individuals.
Thus, individuals and health professionals would need to
inquire about fewer lifestyle factors, avoiding the use of
long questionnaires and minimizing the burden of data col-
lection on both the patient and clinician side. However, for
a comprehensive lifestyle recommendation, all healthy be-
haviours could be considered in additional counselling. The
model performance among women was modest, and better
in men, likely because some risk factors were more strongly
associated with risk among men. The general distribution
and influence of risk factors may differ geographically
across populations and additional model elaboration and
adaptation of country-specific risk models should be further
considered. Ultimately, research is needed to assess the
feasibility and effectiveness of the current lifestyle-based
risk assessment tool on health behaviour modification,
colorectal cancer risk factor improvement, and overall po-
tential for colorectal cancer prevention when incorporated
into the primary care setting, particularly as a pre-screening
instrument of high-risk patients. More work is also war-
ranted for the refinement of the risk communication tool
before its general integration into practice. Finally, in future
research, additional predictors, including relevant bio-
marker and genetic variables, should be further explored on
the way towards improved precision prevention of colorec-
tal cancer. For example, in a systematic review of 29 studies,
addition of common single nucleotide polymorphisms
(SNPs) to other risk factors in models developed in asymp-
tomatic individuals in the general population increased
model discrimination by 0.01 to 0.06 [19]. Overall, the re-
ported C-statistic ranged from 0.56 to 0.63 for SNPs alone
and in combination with other risk factors, respectively
[19]. Further studies are warranted to evaluate whether
employing genetic risk profiling beyond established risk fac-
tors can be useful to identify individuals at high colorectal
cancer risk.
Our work has several strengths. The EPIC study pro-
vided an ideal setting to develop a lifestyle-based colo-
rectal cancer risk prediction model, given its large
sample size, various population backgrounds and a long
follow-up time of over 20 years. Furthermore, the study
provided a variety of objectively measured anthropomet-
ric data along with dietary and lifestyle information.
Therefore, the current model is the first developed on a
European-wide study population sample, allowing as-
sessment of risk across a broad range of diet and lifestyle
behaviours. Given the large sample size, we were also
able to validate the risk scores in an independent subset
of the EPIC populations. Additionally, we derived the
colorectal cancer risk estimates empirically following
state-of-the-art and novel machine learning approaches,
i.e. random survival forest, considering various predic-
tors simultaneously and the gradient in risk across the
full distribution of risk levels. Finally, we considered
model application and suggested a nomogram and a web-
tool to enable risk communication. Several potential limi-
tations of our study warrant discussion. First, we derived
the risk equations based on a study population comprising
of volunteers. Volunteer-based studies are prone to in-
clude individuals who are often more likely to have
favourable exposure and health profiles compared to those
who do not. Thus, higher prevalence of healthy behaviours
in our sample as compared to the general population
could have resulted in overestimated absolute risk esti-
mates. Second, with the exception of age and the an-
thropometric measures, we relied on data of self-reported
predictors and routinely collected cancer outcomes.
Though any risk prediction tool made publicly available
online would also rely on self-reported data, more accur-
ate risk factor ascertainment would possibly improve over-
all model discrimination and calibration. Nevertheless, our
model has shown a good discrimination and excellent cali-
bration. Third, dietary data was collected using food fre-
quency questionnaires as a commonly applied dietary
assessment method in epidemiology, however future
model application should consider further adaptation and
feasibility assessment to facilitate model communication
in practice. Fourth, we based analyses on lifestyle informa-
tion collected at study baseline and, therefore, could not
account for potential behavioural changes during study
follow-up. Finally, the model was developed based on data
available in the EPIC cohort and did not include some po-
tentially important predictors, such as NSAID use or fam-
ily history of colorectal cancer. However, we have
conducted a sensitivity analysis using data from study cen-
tres that collected these data and the model performance
was not altered.
Conclusions
Despite being one of the leading causes of cancer mor-
bidity and mortality, colorectal cancer is largely prevent-
able. LiFeCRC score based on age and lifestyle data
accurately identifies individuals at risk for incident colo-
rectal cancer in European populations and could con-
tribute to improved prevention through motivating
lifestyle change at the individual level.
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consumption, smoker, physically inactive, 80 g daily vegetable intake, 70 g
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